Recent discovery and development of endothelin receptor antagonists

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al.: Novel potent vasoconstrictor peptide produced by vascular endothelin cells. Nature (1988) 332:311–415.
   Google Scholar
• ••Discovery of endothelin.
   Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The human endothelin family: three structurally and pharmaco-logically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA (1989) 8 6 : 2863–2867 .
   Google Scholar
• ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730–732.
   PubMed Web of Science ®Google Scholar
• •ETA receptors.
   Google Scholar
• SAKURAI T, YANAGISAWA M, TAKUWA Y eta].: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732–735.
   Google Scholar
• •ETB receptors.
   Google Scholar
• SAKAMOTO A, YANAGISAWA M, SAKURAI T et al: Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem. Biophys. Res. Commun. (1991) 178:656–663.
   PubMed Web of Science ®Google Scholar
• HOSODA K, NAKAO K, ARAI H et al: Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. (1991) 187:23–26.
   Google Scholar
• OGWA Y, NAKAO K, ARAI H etal.: Molecular cloning of a non-isopeptide selective human endothelin receptor. Biochem. Biophys. Res. Commun. (1992) 178:248–255.
   Web of Science ®Google Scholar
• STEWART D: Update on endothelin. Can. J Cardiol. (1998):11D–13D.
   Google Scholar
• KRUM H, VISKOPER RJ, LACOURICERE Y, BUDDE M, CHARLEON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl. J Med. (1998) 338 (12):784–790.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial data of bosentan.
   Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M et al: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 384(6607)353–355.
   Google Scholar
• MULDER P, RICHARD V, DERUMEAUX G et al: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation (1997) 96 (6):1976–1982.
   Google Scholar
• GIVERTZ MM, COLUCCI WS: New targets for heart-failure therapy: endothelin, inflammatory cytokines and oxidative stress. Lancet (1998) 1520 (Suppl. D:343–338.
   Google Scholar
• SCHIFFRIN EL, INTENGAN HD, THIBAULT G, TOUYZ RM: Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. (1997) 1 2 (0354–367.
   Google Scholar
• WEBB DJ, STRACHAN FE: Clinical experience with endothelin antagonists. Am. J. Hypertension (1998) 11(4) Pt. 3:71S–79S.
   Google Scholar
• COLUCCI WS: Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. (1997) 80 (11A):15L–25L.
   Google Scholar
• TAKAHASHI K, TOTSUNE K, MOURI T: Endothelin in chronic renal failure. Nephron (1994) 66:373–379.
   PubMed Web of Science ®Google Scholar
• COSENTINO F, KATUSIC ZS: Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm? Stroke (1994) 25:904–908.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V, BURRI K et al: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365:759–761.
   PubMed Web of Science ®Google Scholar
• ••Bosentan.
   Google Scholar
• ISHIKAWA K, FUKAMI T, NAGASE T et al.: Cyclic pentapeptide endothelin antagonists with ETA selectivity. Potency and solubility enhancing modifi-cations. J Med. Chem. (1992) 35:2139–2142.
   Google Scholar
• •Discovery of BQ123.
   Google Scholar
• WU C, CHAN MF, STAVROS F et al.: Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med. Chem. (1997) 40 (10:1690–1697.
   PubMedGoogle Scholar
• ••SAR that led to sitaxsentan.
   Google Scholar
• TILTON RG, MUNSCH CL, SHERWOOD SJ et al.: Attenua- tion of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETA receptor antagonist. Pulmonary Pharmacol. Ther. (2000) 13:87–97.
   PubMed Web of Science ®Google Scholar
• •In vivo animal model data of TBC11251.
   Google Scholar
• GIVERTZ MM, COLUCCI WS, LEJEMTEL TH et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101 (25):2922–2927.
   PubMed Web of Science ®Google Scholar
• ••Phase II clinical trial data of sitaxsentan (TBC11251).
   Google Scholar
• WU C, DECKER ER, BLOK N et al.: Endothelin antago-nists: substituted mesitylcarboxamides with high potency and selectivity for ETA receptors. J. Med. Chem. (1999) 42 (22):4485–4499.
   PubMedGoogle Scholar
• WU C, DECKER ER, BLOK N et al.: Discovery of potent,orally available, ETA selective endothelin antagonists: TBC3214 and TBC3711. 219th ACS National Meeting San Francisco, CA, USA (26–30 March, 2000). Book of Abstracts: ORGN 233.
   Google Scholar
• STEIN PD, HUNT JT, FLOYD DM eta].: The discovery ofsulfonamide endothelin antagonists and the develop-ment of the orally active ETA antagonist 5-(dimethyl-amino)-N-(3,4-dimethy1-5-isoxazoly1)-1-naphthalenes ulfonamide. J Med. Chem. (1994) 37:329–331.
   Google Scholar
• MURUGESAN N: Discovery of BMS-193884, a potent and selective ETA receptor antagonist. 219th ACS National Meeting San Francisco, CA, USA (26–30 March, 2000). Book of Abstracts: MEDI 164.
   Google Scholar
• ••Discloses the discovery and Phase II trial data onBMS-193884.
   Google Scholar
• DOHERTY AM, PATT WC, EDMUNDS JJ et al.: Discoveryof a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J Med. Chem. (1995) 38:1259–1263.
   PubMed Web of Science ®Google Scholar
• CHENG XM, LEE C, REPIN JT et al.: PD180988, a potentETA selective antagonist and its therapeutic potential. 217th ACS National Meeting Anaheim, CA, USA (21–25 March, 1999). Book of Abstracts: MEDI 135.
   Google Scholar
• WINN M, VON GELDERN TVV, OPGENORTH TJ et al.: 2,4-Diarylpyrrolidine-3-carboxylic acids-potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. (1996) 39:1039–1048.
   Google Scholar
• LIU G, HENRY KJ, JR., SZCZEPANKIEWICZ BG et al.:Pyrrolidine-3-carboxylic acids as endothelin antago-nists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546). J Med. Chem. (1998) 41:3261–3275.
   Google Scholar
• XIANG JN, LUENGO JI, OHLSTEIN EH, ELLIOT JD:Endothelin receptor antagonists. 217th ACS National Meeting. Anaheim, CA, USA (21–25 March, 1999). Book of Abstracts: MEDI 136.
   Google Scholar
• BIALECKI RA: Endothelin-1: cardiovascular physiology, pharmacology and a putative role in the pathogenesis of pulmonary hypertension. 217th ACS National Meeting. Anaheim, CA, USA (21–25 March 1999). Book of Abstracts: MEDI 134.
   Google Scholar
• ASTLES PC, BROWN TJ, HALLEY F et al.: Selective ETAantagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid deriva-tives. J. Med. Chem. (2000) 43:900–910.
   Google Scholar
• HAESSLEIN JL, BAHOLET I, FORTIN M et al.:1,3-Disubstituted-2-carboxy quinolones: highly potent and selective endothelin A receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10:1487–1490.
   Google Scholar
• ISHIKAWA K, IHARA M, NOGUCHI K et al: Biochemicaland pharmacological profile of a potent and selective endothelin B-receptor antagonist BQ-788. Proc. Natl. Acad. Sci. USA, (1994) 91:4892–4896.
   PubMed Web of Science ®Google Scholar
• BREU V, CLOSZEL M, BURRI K et al.: In vitro characterisa-tion of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ET-B receptor. FEBS Lett. (1996) 383(1-2):37–41.
   PubMedGoogle Scholar
• CHAN MF, KOIS A, VERNER EJ et al.: The discovery andstructure-activity relationshiops of nonpep tide, low molecular weight antagonists selective for the endothelin ETB receptor. Bioorg. Med. Chem. (1998) 6:2301–2316.
   PubMed Web of Science ®Google Scholar
• VON GELDERN TW, TASKER AS, SORENSEN BK et al: Pyrrolidine-3-carboxylic acids as endothelin antago-nists. 4. Side chain conformational restriction leads to ETB selectivity. J Med. Chem. (1999) 42 (18):3668–3678.
   Google Scholar
• LIU G, KOZMINA NS, WINN M et al.: Design, synthesis and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ETB antago-nists containing a diphenylmethylamine acetamide side chain. J Med. Chem. (1999) 42 (18):3679–3689.
   Google Scholar
• CLOZEL M, BREY V, GRAY GA: Pharmacological charac-terization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1994) 270:228–235.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, RAMUZ H, CLOZEL JP et al.: Preclinical andclinical pharmacology of tezosentan, a new endothelin receptor antagonist designed for parenteral use. 6th International Conference on Endothelin Montreal, Canada (10–13 October, 1999). Book of Abstracts: 049.
   Google Scholar
• ELLIOTT JD, LAGO MA, COUSINS RD et al.: 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antago-nists./ Med. Chem. (1994) 37:1553–1557.
   Google Scholar
• OHLSTEIN EH, NAMBI P, LARGO A et al.: Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of 5B217242, a potent and highly bioavailable endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276 (2) :609–615.
   Google Scholar
• JAE HS, WINN M, DIXON DB et al.: Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/E1B mixed antagonists./ Med. Chem. (1997) 40 (203217–3227.
   Google Scholar
• WALSH TF, FITCH K J, CHAKRAVARTY K et al: 208th ACS National Meeting. Washington, DC, USA (21–25 August, 1994). Book of Abstracts: MEDI 145.
   Google Scholar
• AMBERG W, HERGENRODER S, HILLEN H et al.: Discovery and synthesis of (5)-342-(3,4-dimethoxy phenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy) -3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ETA/ETB receptor antagonist. J Med. Chem. (1999) 42(16):3026–3032.
   PubMed Web of Science ®Google Scholar
• NISHIKIBE M, OHTA H, OKADA M et al.: Pharma-cological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/FIB endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1999) 289(3):1262–1270.
   Google Scholar
• IKEDA S, AWANE Y, KUSUMOTO K et al.: A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J. Pharmacol Exp. Ther. (1994) 270:728–733.
   PubMed Web of Science ®Google Scholar